PulseCheck” is a series within CardiaCast that is designed for Cardiovascular (CV) Team members who are new, or new to ...

In this week’s View, Dr. Eagle looks at the consequences of discontinuing long-term drug treatment in patients with heart ...

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

In this special edition of Eagle’s Eye View, Dr. Eagle looks four of the most important trials presented at the recent TCT Conference: 1) EARLY TAVR evaluating TAVR compared to clinical surveillance; ...

A small proportion of patients with STEMI treated via primary PCI experienced late ventricular tachycardia (VT) or ventricular fibrillation (VF), occurring one or more days following the procedure, ...

Galli M, Gragnano F, Berteotti M, et al., on behalf of the Working Group of Thrombosis of the Italian Society of Cardiology. Citation: Antithrombotic Therapy in High Bleeding Risk Part II: Non-Cardiac ...

You care for a 75-year-old woman with heart failure (HF) with reduced ejection fraction. For the years you have known her, she has enjoyed spending time with her grandchildren, living independently ...

The release of the ACC/AHA Focused Update on the Duration of Dual Antiplatelet Therapy (DAPT) represents an important event, in that its findings impact six already released ACC/AHA Clinical Practice ...

The ACC's Guideline Clinical App is the mobile home of clinical guideline content and tools for clinicians caring for patients with cardiovascular disease. The App brings the guidelines closer to the ...

The newest clinical guideline released by the ACC and American Heart Association (AHA), in collaboration with seven other societies, provides updated recommendations for perioperative cardiovascular ...

Can algorithms improve the management of patients with myocardial injury? Is there a tool to aid diagnosing patients faster ...

Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood Pressure Lower Treatment in ...